<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920448</url>
  </required_header>
  <id_info>
    <org_study_id>20-079</org_study_id>
    <nct_id>NCT04920448</nct_id>
  </id_info>
  <brief_title>N-ACETYLCYSTEINE FOR THROMBOLYSIS IN ACUTE STROKE</brief_title>
  <acronym>NAC-S</acronym>
  <official_title>TOLERANCE STUDY OF N-ACETYLCYSTEINE FOR THROMBOLYSIS IN THE ACUTE PHASE OF ISCHEMIC STROKE / ETUDE DE TOLERANCE DE LA N-ACETYLCYSTEINE POUR LA THROMBOLYSE A LA PHASE AIGUË DE L'INFARCTUS CEREBRAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety of N-Acetylcysteine as a&#xD;
      thrombolytic agent in acute ischemic stroke, especially regarding the risk of hemorrhagic&#xD;
      transformation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preclinical studies demonstrated that N-Acetylcysteine (NAC) is able to break von Willebrand&#xD;
      Factor (VWF) multimers by bisulfide bond reduction. Since thrombi in stroke patients are rich&#xD;
      in VWF, NAC could be used as a thrombolytic agent during the acute phase. This study aims at&#xD;
      assessing the safety of NAC in combination with alteplase (rt-PA) at the acute phase of&#xD;
      ischemic stroke.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 7, 2021</start_date>
  <completion_date type="Anticipated">September 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 8, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic intracranial hemorrhagic transformation</measure>
    <time_frame>22 to 36 hours after treatment</time_frame>
    <description>Rate of symptomatic hemorrhagic transformation according to the SITS-MOST criteria: a local or remote parenchymal hemorrhage on imaging 22 to 36 hours after treatment or earlier if the imaging scan was performed due to clinical deterioration combined with a neurological deterioration of &gt;4 NIHSS points from baseline or from the lowest NIHSS score between baseline and 24 hours or leading to death within 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extracranial hemorrhagic events</measure>
    <time_frame>Up to 3 months after treatment</time_frame>
    <description>Rate of extracranial hemorrhagic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related side effects</measure>
    <time_frame>Up to 3 months after treatment</time_frame>
    <description>Rate of any drug related side effects according to the Common Terminology Criteria of Adverse Event 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality and functional independence</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>Rate of mortality and functional independence at 3 months according to the modified Rankin scale (mRs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early neurological improvement</measure>
    <time_frame>24 hours after treatment</time_frame>
    <description>Rate of early neurological improvement defined as an improvement of &gt;4 NIHSS points 24 hours after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma VWF multimers</measure>
    <time_frame>Before, at 3 hours and at 24 hours after treatment</time_frame>
    <description>Mean size of VWF multimers before and after treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>N-Acetylcysteine 150 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous injection of N-Acetylcysteine (150 mg/kg in 15 minutes).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetyl cysteine</intervention_name>
    <description>Administered as specified in the treatment arm</description>
    <arm_group_label>N-Acetylcysteine 150 mg/kg</arm_group_label>
    <other_name>HIDONAC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient presenting with an acute ischemic stroke (non lacunar) as assessed by cerebral&#xD;
             imaging (either CT or MRI), with or without visible vessel occlusion.&#xD;
&#xD;
          -  Patient eligible to intravenous thrombolysis according to current criteria, including&#xD;
             patients who will also benefit from endovascular treatment (if eligible).&#xD;
&#xD;
          -  Personal or familial consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to N-Acetylcysteine or to any excipient from the formulation.&#xD;
&#xD;
          -  Coma and/or NIHSS &lt;4 or ≥20.&#xD;
&#xD;
          -  Daily treatment with Nitrovasodilator before the inclusion.&#xD;
&#xD;
          -  Known asthma or chronic obstructive pulmonary disease requiring bronchodilatators or&#xD;
             steroids.&#xD;
&#xD;
          -  Participation to another interventional study if it requires administration of an&#xD;
             experimental treatment in the first 3 days after NAC treatment.&#xD;
&#xD;
          -  Women of childbearing age (age &lt; or = to 50)&#xD;
&#xD;
          -  Known history of prior treatment with vitamin-K antagonist or direct oral&#xD;
             anticoagulant.&#xD;
&#xD;
          -  Known history of severe hepatopathy including cirrhosis, portal hypertension&#xD;
             (esophageal varices) and evolutive hepatopathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marion Boulanger, MD, PhD</last_name>
    <phone>+33231064617</phone>
    <email>boulanger-ma@chu-caen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <state>Normandy</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marion Boulanger, MD, PhD</last_name>
      <phone>+33231064617</phone>
      <email>boulanger-ma@chu-caen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emmanuel TOUZE, MD, PhD</last_name>
      <phone>+33231064617</phone>
      <email>touze-e@chu-caen.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Martinez de Lizarrondo S, Gakuba C, Herbig BA, Repessé Y, Ali C, Denis CV, Lenting PJ, Touzé E, Diamond SL, Vivien D, Gauberti M. Potent Thrombolytic Effect of N-Acetylcysteine on Arterial Thrombi. Circulation. 2017 Aug 15;136(7):646-660. doi: 10.1161/CIRCULATIONAHA.117.027290. Epub 2017 May 9.</citation>
    <PMID>28487393</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombolysis</keyword>
  <keyword>Hemorrhagic transformation</keyword>
  <keyword>Alteplase</keyword>
  <keyword>Thrombectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

